Q BioMed Inc. Provides Update to Shareholders - June 23, 2023

Q BioMed Inc., a biotech acceleration and commercial stage company, has provided an update to shareholders regarding its financials and OTC listing compliance. The company was unable to file complete audited financials for 2022 due to capital constraints and costs associated with the audit process. As a result, it filed an un-audited annual report for 2022 and Q1 2023 but was downgraded to the '..

  • format_list_bulleted BS
  • · 2023. 6. 26.
  • textsms

Molecular Templates Announces Debt Payoff and Restructuring

Molecular Templates, a clinical-stage biopharmaceutical company focused on developing targeted biologic therapeutics for cancer, has announced a restructuring agreement with K2 HealthVentures to fully discharge and satisfy outstanding debt obligations. The agreement also includes the granting of contingent value rights and warrants. Molecular Templates will reduce its current workforce by approx..

  • format_list_bulleted BS
  • · 2023. 6. 19.
  • textsms